Navigation Links
Kinexus Announces the Launch of New Peptide Production Services
Date:3/16/2010

New Peptide Array Facility Designed to Expedite the Drug Discovery Process

VANCOUVER, March 16 /PRNewswire/ - Kinexus Bioinformatics Corporation, a world leader in functional proteomics research, announced the launch of a new peptide synthesis facility to provide researchers with the latest in peptide array technologies. These new services will facilitate and expedite access to peptide platforms for innovative approaches to proteomic research and discovery. A variety of peptide services are being made available by Kinexus to the research community including:

    -   Protein Labeling,
    -   Screening of peptide arrays like Epitope Mapping, Substitution
        Analysis, and Peptide Library Screening,
    -   Custom Peptide Synthesis including modified peptides like
        phosphopeptides, histones, cyclized and labeled peptides,
    -   CelluSpots(TM) Custom Peptide Arrays on Glass Slides, and
    -   CelluSpots(TM) Kinase Substrate Peptide Arrays on Glass Slides.

"Kinexus' peptide-based products strongly complement our existing portfolio of cell signaling, proteomics and bioinformatics services," stated Dr. Steven Pelech, president and Chief Scientific Officer of Kinexus Bioinformatics Corporation. "These new products will give Kinexus customers access to high-throughput peptide synthesis and screening platforms, which will accelerate research in the field of signal transduction. The Peptide Array Facility is the latest addition to a unique integrated suite of proteomics services offered by Kinexus which delivers solutions and services for pharmaceutical, biotechnology, academic, life science, clinical and government research laboratories from around the world.

To learn more about the new Peptide Production Services or any of the other proteomics services available, please visit www.kinexus.ca. Kinexus Bioinformatics Corporation is a privately held, biotechnology company engaged in the research and development of innovative methods to understand the relationships of signaling proteins in molecular communication networks. The application of this knowledge positions Kinexus and its clients in drug development, rational drug design, disease diagnosis and personalized therapies to improve human health.

SOURCE Kinexus Bioinformatics Corporation

Back to top
'/>"/>
SOURCE Kinexus Bioinformatics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kinexus Announces the Launch of a New Protein Kinase Microarray
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):